Skip to main content

Too Few Visible Catalysts For Revance Push Guggenheim to The Sidelines

By: via Benzinga
Revance Therapeutics Inc (NASDAQ: RVNC) announced interim Phase 2a results for RT002 in treating Plantar Fasciitis, which showed ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.